



# ADAMTS13

## A Disintegrin and Metalloprotease with ThromboSpondin Motifs

### Background:


- ADAMTS13 cleaves very specific large vWF multimers under laminar flow conditions. A functional defect of ADAMTS13 leads to presence of higher molecular weight forms of vWF in plasma and thus to increased platelet aggregation.
- Thrombotic microangiopathy (TMA) is a pathologic state which results in thrombosis in capillaries and arterioles, due to an endothelial injury. The classic TMAs are atypical hemolytic uremic syndrome (aHUS) and TTP. TTP occurs at a very low ADAMTS13 activity concentration.

## TECHNOZYM ADAMTS13 Activity ELISA #5450701-US

- Calibrators and Controls are traceable to WHO 1st international Standard ADAMTS13 plasma (NIBSC code 12/252)
- No interference by bilirubin, lipemic samples up to 500 mg/dL, or hemolytic samples up to 220 mg/dL


### Intact Vessel Wall

ADAMTS13 regulates under normal circumstance the size of vWF multimers




### Injured/Inflamed Vessel Wall

vWF multimers build a connection between collagen and platelets




### Absence of ADAMTS13

Formation of very large vWF multimers leads to platelet aggregation in healthy vessels TTP



### Test Principle



### Kit Contents

- 12 x 8 Anti-GST strips
- 1 x 12 ml HRP Conjugate
- 1 x 30 ml Reaction Buffer

- 1 x 53 ml Wash Buffer Concentrate
- 1 x 12 ml TMB Substrate
- 2 x 6 ml GST-vWF73 Substrate

- 1 x 12 ml Stop Solution
- 8 x 0.5 ml Calibrators and Controls\*

\*Additional calibrators & controls available separately.